Fmr LLC Boosts Stake in China Biologic Products Holdings Inc (CBPO)

Share on StockTwits

Fmr LLC grew its position in shares of China Biologic Products Holdings Inc (NASDAQ:CBPO) by 64.6% in the fourth quarter, Holdings Channel reports. The fund owned 737,579 shares of the biopharmaceutical company’s stock after buying an additional 289,485 shares during the quarter. Fmr LLC’s holdings in China Biologic Products were worth $55,990,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CBPO. AdvisorNet Financial Inc bought a new position in shares of China Biologic Products during the 4th quarter valued at approximately $57,000. Cutler Group LP lifted its position in China Biologic Products by 58.4% in the fourth quarter. Cutler Group LP now owns 1,356 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 500 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its position in China Biologic Products by 79.9% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 2,100 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 933 shares during the last quarter. Legal & General Group Plc lifted its position in China Biologic Products by 25.2% in the third quarter. Legal & General Group Plc now owns 2,357 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 475 shares during the last quarter. Finally, Athos Capital Ltd bought a new stake in China Biologic Products in the fourth quarter worth $849,000. Hedge funds and other institutional investors own 37.25% of the company’s stock.

CBPO has been the subject of a number of analyst reports. BidaskClub upgraded China Biologic Products from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Jefferies Financial Group downgraded China Biologic Products from a “hold” rating to an “underperform” rating and lowered their price target for the stock from $67.00 to $62.00 in a research report on Monday, March 11th. Credit Suisse Group set a $88.00 price target on China Biologic Products and gave the stock a “hold” rating in a research report on Friday, March 8th. ValuEngine upgraded China Biologic Products from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Finally, Zacks Investment Research upgraded China Biologic Products from a “strong sell” rating to a “hold” rating in a research report on Monday, January 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $78.00.

Shares of CBPO opened at $96.85 on Wednesday. The firm has a market capitalization of $3.79 billion, a P/E ratio of 23.49, a P/E/G ratio of 5.10 and a beta of 1.26. China Biologic Products Holdings Inc has a 52-week low of $60.08 and a 52-week high of $107.44.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported $0.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.07). The company had revenue of $114.90 million during the quarter, compared to the consensus estimate of $116.35 million. China Biologic Products had a return on equity of 9.54% and a net margin of 27.43%. The firm’s quarterly revenue was up 27.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.32 earnings per share. On average, analysts anticipate that China Biologic Products Holdings Inc will post 3.78 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Fmr LLC Boosts Stake in China Biologic Products Holdings Inc (CBPO)” was first published by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://macondaily.com/2019/04/17/fmr-llc-boosts-stake-in-china-biologic-products-holdings-inc-cbpo.html.

China Biologic Products Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Story: Depreciation

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings Inc (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.